The funding will assist the development of two applications into scientific trials and the event of a pipeline of novel pre-clinical applications for the therapy of melancholy and different neuropsychiatric issues
NEW YORK, Dec. 15, 2022 /PRNewswire/ — Gilgamesh Prescribed drugs, a biotechnology firm growing a portfolio of rapid-acting and sturdy remedies for melancholy and different psychological well being issues, at this time introduced the closing of a $39 million Sequence B spherical of financing. The spherical was led by Prime Movers Lab with extra funding from Alumni Ventures, Palo Santo, Negev Capital, Route 66, JLS Fund, Satori Capital and Gron Ventures. The extra capital might be used, partially, to additional advance Gilgamesh’s 2 lead applications, GM-1020 and GM-2505 by means of Part 1/1b security and efficacy research.
GM-1020 is a novel, patented (composition of matter), orally lively small molecule antagonist of the N-methyl-D-aspartate (NMDA) receptor with the potential to have rapid-acting antidepressant (RAAD) exercise with out opposed behavioral results at therapeutic doses. GM-1020 is orally bioavailable and retains speedy and strong results in preclinical fashions of melancholy whereas avoiding unwanted effects sometimes related to IV ketamine and IN esketamine. Collectively, these properties could make GM-1020 appropriate for at-home use, lowering the burden of therapy and rising compliance.
GM-2505 is a novel, patented (composition of matter), small molecule, short-acting 5-HT2A receptor agonist/5-HT releaser that’s anticipated to have a speedy and sturdy antidepressant impact. GM-2505 is anticipated to supply dramatic adjustments in human consciousness, notion, emotion, and cognition. As well as, the 5-HT releaser element could add empathogenic options to the affected person expertise. GM-2505 was designed to have an excellent PK profile in people, permitting for ample goal engagement to supply RAAD results with out requiring a burdensome, extended-duration in-clinic expertise, thereby considerably lowering the affected person/therapist time. Consequently, given the restricted variety of skilled therapists, Gilgamesh hopes to have the ability to deal with many instances extra sufferers than longer-duration options.
Gilgamesh not too long ago introduced preclinical information highlighting GM-1020 and GM-2505 on the 61st Annual Assembly of the ACNP (American Faculty of Neuropsychopharmacology) in December 2022.
Gilgamesh can also be advancing a number of discovery applications that can gasoline its pipeline over the approaching years. To allow this effort, Gilgamesh makes use of a platform of cutting-edge preclinical applied sciences to information compound choice, together with machine-learning evaluation of animal conduct and high-resolution electrophysiology, by means of collaborations with main educational laboratories (for extra particulars consult with the latest article in Nature Biopharma Dealmakers).
To additional bolster Gilgamesh’s discovery efforts, John Macor Ph.D. has joined as a Senior Adviser. Dr. Macor not too long ago served because the World Head of Built-in Drug Discovery at Sanofi and is presently Chief Scientific Officer at Sionna Therapeutics. He’ll leverage his a long time of chemistry and discovery experience, together with in serotonin and NMDA receptor structure-activity relationships (SAR), to advance Gilgamesh’s pipeline of neuropsychiatric remedies. Dr. Macor is an inductee of the ACS Medicinal Chemistry Corridor of Fame, and is a co-inventor of two marketed medication (Relpax™ and Nurtec™ ODT).
“Greater than 280 million folks undergo from melancholy world wide, but the best way we deal with melancholy has remained stagnant for many years. Our mission is to essentially reshape the therapy of psychological sickness,” mentioned CEO and co-founder Dr. Jonathan Sporn. “Regardless of a normal dip in fundraising within the life sciences sector this yr, corporations with robust science and technique, similar to Gilgamesh, are nonetheless in a position to increase capital. We’re excited to proceed our partnership with Prime Movers Lab to carry our most promising remedies into part 1 trials.”
“Gilgamesh has made vital strides with its trial candidates and constructed a world-class crew,” mentioned Prime Movers Lab Common Companion and Gilgamesh Board Member Amy Kruse. “Gilgamesh is positioned on the forefront of an rising revolution within the therapy of psychiatric issues, with a pipeline of novel brokers that advance the therapeutic results of psychoactive substances.”
About Gilgamesh Prescribed drugs
Gilgamesh is a pioneering, psychological well being science-focused biotechnology firm. We now have a disciplined concentrate on growing modern new chemical entities (NCEs) leveraging a novel mixture of medicinal chemistry, mental property technique, neuroscience & neurobiology, and drug improvement experience. We’re an skilled crew, with confirmed success in biotech exits and innovations. For extra data, go to: www.gilgameshpharmaceutical.com.
About Prime Movers Lab
Prime Movers Lab invests in breakthrough scientific startups based by Prime Movers, the inventors who rework billions of lives. We put money into corporations reinventing vitality, transportation, infrastructure, manufacturing, agriculture and human augmentation. Portfolio investments span in-space transportation, industrial photo voltaic warmth, ag tech, mind upgrades, nano-structured supplies, wafer slicing, prosthetics, 3D printing, mobility, longevity and AI. For extra data, please go to https://www.primemoverslab.com.
SOURCE Gilgamesh Prescribed drugs